Agree bfw ..... among the issues we face, and other than those related strictly to RVX corporate, company viability, BoM success ..... is simply "acceptance" within the medical community. It's new, a new frontier, we need good study results, approval, and a movement within the medical community to accept this new era ..... which then opens the door wide open for RVX-208 in Renal, Cognitive, and potentially a host of other things as other indications try it off label and push the "old school" and Ivory Tower thinking. Oh, and what about those other 3000 molecules?! ...... if RVX-208 hits, it could even dwarf the already "big picture" we have discussed in Diabetic Cardiopathy, Renal, Cognitive ... maybe?

Yes, Nasdaq, and collaborating with other BP's once RVX-208 is approved ... could be a very intersting ride for investors, and an incredible new era helping to pave the future in medicine as well.

Time will tell, JMHO and hope ...